Honokiol sensitizes breast cancer cells to TNF‐α induction of apoptosis by inhibiting Nur77 expression

Xie, Lei; Jiang, Fuquan; Zhang, Xindao; Alitongbieke, Gulimiran; Shi, Xiaohu; Meng, Minjun; Xu, Yiming; Ren, Anshi; Wang, Jing; Cai, Liang; Zhou, Yunxia; Xu, Yang; Su, Ying; Liu, Jie; Zeng, Zhiping; Wang, Guanghui; Zhou, Hu; Chen, Quan Cheng; Zhang, Xiaokun

doi:10.1111/bph.13375

Cited by 26 publications

(22 citation statements)

References 49 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,[23][24][25][26][27][28] Intravenous administration of chemotherapeutic agents has been accepted as a conventional approach for antitumor chemotherapy. However, the hydrophobicity of PTX and HK had limited its use in clinical practice.…”

mentioning

confidence: 99%

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo

Wang¹,

Wang²,

Nie³

et al. 2017

IJN

View full text Add to dashboard Cite

The combination of chemotherapy drugs attracts more attention in clinical cancer trials. However, the poor water solubility of chemotherapeutic drugs restricts their anticancer application. In order to improve antitumor efficiency and reduce side effects of free drugs, we prepared paclitaxel (PTX) and honokiol (HK) combination methoxy poly(ethylene glycol)–poly(caprolactone) micelles (P–H/M) by solid dispersion method against breast cancer. The particle size of P–H/M was 28.7±2.5 nm, and transmission electron microscope image confirmed that P–H/M were spherical in shape with small particle size. After being encapsulated in micelles, the release of PTX or HK showed a sustained behavior in vitro. In addition, both the cytotoxicity and the cellular uptake of P–H/M were increased in 4T1 cells, and P–H/M induced more apoptosis than PTX-loaded micelles or HK-loaded micelles, as analyzed by flow cytometry assay and Western blot. Furthermore, the antitumor effect of P–H/M was significantly improved compared with PTX-loaded micelles or HK-loaded micelles in vivo. P–H/M were more effective in inhibiting tumor proliferation, inducing tumor apoptosis, and decreasing the density of microvasculature. Moreover, bioimaging analysis showed that drug-loaded polymeric micelles could accumulate more in tumor tissues compared with the free drug. Our results suggested that P–H/M may have potential applications in breast cancer therapy.

show abstract

mentioning

confidence: 99%

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo

Wang¹,

Wang²,

Nie³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Figure 6). 19 In our study, we found that NR4A1 was highly expressed in TRAIL-resistant HCC cells. ISG12a-S has a stronger ability to induce apoptosis than the full length ISG12a.…”

Section: Trail Induces Nr4a1 Expression Partly Through Nf-κb Pathwaymentioning

confidence: 52%

“…19 The siRNA sequences To obtain a high knockdown efficiency, 50 nmol/L siRNA was used. 19 The siRNA sequences To obtain a high knockdown efficiency, 50 nmol/L siRNA was used.…”

Section: Plasmids and Sirna Transfectionmentioning

confidence: 99%

“…19 To test whether TRAIL has a similar ability to induce NR4A1 expression in hepatoma cells, we treated LH86 and Huh7 cells with TRAIL and examined NR4A1 expression by Western blot. 19 To test whether TRAIL has a similar ability to induce NR4A1 expression in hepatoma cells, we treated LH86 and Huh7 cells with TRAIL and examined NR4A1 expression by Western blot.…”

Section: Trail Induces Nuclear Accumulation Of Nr4a1 In Trail-resismentioning

confidence: 99%

“…The siRNA sequence for NR4A1 (5′-GGCUUGAGCUGCAGAAUG AdTdT-3′) was previously reported. 19 The siRNA sequences To obtain a high knockdown efficiency, 50 nmol/L siRNA was used. Cells were transfected with siRNA or plasmids for 48 hours and then treated with TRAIL or inhibitors at indicated times.…”

Section: Plasmids and Sirna Transfectionmentioning

confidence: 99%

See 2 more Smart Citations

ISG12a and its interaction partner NR4A1 are involved in TRAIL‐induced apoptosis in hepatoma cells

Liu

Chen

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) can induce apoptosis in cancer cells while sparing normal cells, thereby leading to the development of TRAIL receptor agonists for cancer treatment. However, these agonist‐based therapeutics exhibit little clinical benefits due to the lack of biomarkers to predict whether patients are responsive to the treatment, as well as determine the resistance of cancer cells to TRAIL‐based agonists. Our previous study has demonstrated that ISG12a enhances TRAIL‐induced apoptosis and might serve as a biomarker to predict the TRAIL response. The downstream mechanism by which ISG12a augments TRAIL‐induced apoptosis remains to be elucidated. In this study, we found that ISG12a was localized in the mitochondria and nucleus and augmented TRAIL‐induced apoptosis through intrinsic apoptotic pathway. In addition, ISG12a interacted with NR4A1 and promoted its nuclear‐to‐cytoplasm translocation. Upon translocate to cytoplasm, NR4A1 targeted mitochondria and induced Bcl2 conformational change, thereby exposing its BH3 domain. Moreover, TRAIL treatment can induce NR4A1 expression through the activation of NF‐κB in TRAIL‐resistant Huh7 hepatoma cells. Knockdown of NR4A1 could overcome TRAIL resistance. However, in TRAIL‐sensitive LH86 liver cancer cells, TRAIL activated the Jun N‐terminal kinases signalling pathway. Overall, these results showed that both ISG12a and its interaction partner NR4A1 are involved in TRAIL‐mediated apoptosis in hepatoma cells.

show abstract

Honokiol targets mitochondria to halt cancer progression and metastasis

Pan

Lee

Wang

et al. 2016

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Cancer continues to be the leading cause of death worldwide. Plants have a long history of use in the treatment of cancer. Honokiol (HNK) is an important bioactive compound found in the bark of Magnolia tree, and has been shown to inhibit cancer growth and metastasis in many cell types in vitro and in animal models. Resistance to chemotherapy and radiotherapy is the major obstacle for cure of cancer. Combination of HNK with many traditional chemotherapeutic drugs as well as radiation sensitizes cancer cells to apoptotic death, suggesting that HNK not only directly inhibits primary cancers and metastasis, but also has potential to overcome drug resistance. Ultimately, this may mean that HNK could be combined with traditional chemotherapies administered at lower doses to significantly reduce toxicity, meanwhile enhance efficacy. As a natural compound, HNK is composed of polyphenols and has been described in many studies targeting multiple key cell signaling molecules. Mitochondria are the main hub for cellular energy production and play an important role in cell survival, and are the key target identified for HNK to mediate cancer cell death, survival, and metastasis. In this review, we have summarized different aspects of HNK's anti-cancer effects from recent accumulated literature, as well as the underlying molecular mechanisms. This review is primarily focused on the effects of HNK on epidermal growth factor receptor (EGFR) and signal transduction and activator of transcription 3 (STAT3) signaling, as well as the broader regulation of mitochondrial function and cancer cell metabolism.

show abstract

Honokiol sensitizes breast cancer cells to TNF‐α induction of apoptosis by inhibiting Nur77 expression

Cited by 26 publications

References 49 publications

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo

ISG12a and its interaction partner NR4A1 are involved in TRAIL‐induced apoptosis in hepatoma cells

Honokiol targets mitochondria to halt cancer progression and metastasis

Contact Info

Product

Resources

About